Skip to content
Evigrade
MinorOther dermatologicals (topical); peripheral vasodilators (systemic)×Calcineurin inhibitor (immunosuppressant)

Updated · Methodology

Mechanism

CYP3A4 metabolises tacrolimus in the liver and the gut wall. Tacrolimus itself inhibits this enzyme and is more than 98.8% bound to plasma proteins (tacrolimus SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In the liver, minoxidil is mainly conjugated with glucuronic acid. It does not bind to plasma proteins and causes no substantial change in glomerular filtration rate or renal plasma flow (minoxidil tablets SmPC, AEMPS). Between 1% and 2% of the applied dose of scalp foam or solution reaches the circulation (minoxidil scalp foam SmPC, AEMPS). By its own documents, minoxidil does not belong to any group the tacrolimus documents warn about (CYP3A4 inhibitors and inducers, highly protein-bound drugs, drugs harmful to the kidneys, drugs that raise potassium), and no document names the pair.

Symptoms

The documents describe no symptoms of this combination. Tacrolimus very commonly raises blood pressure, commonly causes oedema and hair loss, and rarely pericardial effusion (tacrolimus SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Minoxidil tablets cause salt and water retention and oedema, and pericardial effusion in 3–5% of patients not on dialysis (minoxidil tablets SmPC, AEMPS). If the skin is damaged or the scalp product is misused, more minoxidil may be absorbed. At least in theory, systemic effects may then appear: low blood pressure, a fast heart rate, swelling of the hands and feet (minoxidil scalp foam SmPC, AEMPS).

Management

According to the documents, the combination is acceptable, and the doses of tacrolimus and minoxidil need no change. No document names the pair (tacrolimus SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, and European Medicines Agency, EMA; Prograf label, US Food and Drug Administration, FDA; minoxidil SmPCs, AEMPS; minoxidil tablets label, FDA). Hypertension caused by tacrolimus can be controlled with any of the common antihypertensive agents. Only those associated with hyperkalaemia need careful consideration before use: potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (Prograf label, FDA). In the early post-transplant period, monitor blood pressure, potassium and other electrolytes, and kidney and liver function routinely (tacrolimus SmPC, AEMPS). Tacrolimus can impair kidney function, and in renal impairment minoxidil tablets may need a lower dose. With the tablets, monitor body weight and fluid and electrolyte balance (tacrolimus and minoxidil tablets SmPCs, AEMPS). Fluid overload and oedema are among the risk factors for myocardial hypertrophy during tacrolimus treatment. High-risk patients have echocardiography or an electrocardiogram (ECG) before and after transplantation, for example at baseline, at 3 months and at 9–12 months (tacrolimus SmPC, AEMPS). Minoxidil tablets cause salt and water retention, so they are taken together with a diuretic. Echocardiography is done at any sign of pericardial effusion (minoxidil tablets SmPC, AEMPS). With scalp minoxidil, blood pressure and heart rate are monitored regularly. The product is stopped if any of the following appear: low blood pressure, chest pain, a fast heart rate, weakness or dizziness, sudden weight gain, or swelling of the hands or feet (minoxidil scalp solution and foam SmPCs, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Minoxidil

Other interactions with Tacrolimus